<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 3, 1996
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter)
New Jersey 1-1-432 22-2429994
-------------------- ---------------- --------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 908-389-1182
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
- 2 -
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation announced today that Monarch
Pharmaceuticals, a division of King Pharmaceuticals of Bristol, Tennessee, has
acquired two separate respiratory care product lines from Roberts. The two
product lines involved in the acquisition are Nucofed(R) and Quibron(R).
The Nucofed(R) family of products consists of four separate
dosage forms, all of which are indicated for the symptomatic relief of coughing
and congestion associated with respiratory infections and related conditions
such as the common cold, bronchitis, influenza, and sinusitis. The Quibron(R)
family, consisting of four separate dosage forms is indicated for relief and/or
prevention of symptoms of asthma and reversible bronchospasm associated with
chronic bronchitis and emphysema.
The sale of these two product lines is in keeping with Roberts
plans to divest certain brands in order to concentrate on the commercialization
of Roberts' pipeline.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: October 8, 1996 By: /s/ Anthony A. Rascio
----------------------------
Anthony A. Rascio
Vice President
